P-MAPA immunotherapy and interleukin-12 on ovarian carcinoma SKOV-3 cells: Assessment of the TLR signaling and cytokine/chemokine profile

      Background: Ovarian cancer (OC) is the 5th leading cause of cancer death among women, and presents poor prognosis when diagnosed at a late stage. Despite recent advances in OC managements, patients can acquire chemoresistance after first-line treatments, and tumor progression take place. Novel therapies targeting the immunological system have emerged as promising complementary therapies for OC. The Protein aggregate magnesium-ammonium phospholinoleate-palmitoleate anhydride (P-MAPA) immunotherapy and human recombinant interleukin-12 (IL-12) have showed important effects in solid tumors and might be largely useful against OC development. To evaluate the effects of P-MAPA and IL-12 alone and the combination therapy (P-MAPA + IL-12) on toll-like receptor 2 and 4 (TLR2 and 4)-mediated signaling pathway, cytokine/chemokine secretion and migratory potential in OC cells.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect